Home > Insider Trading > Filing (0001140361-20-018617)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc.	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559537	Paolo Fundaro	Via G. De Grassi, 11 Milan L6 20123		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Disposition	2020-08-13	83,000	$52.60	5,417,000	No	4	S	Indirect	See Footnote
Common Stock, Par Value $0.001 Per Share	Disposition	2020-08-14	54,600	$50.55	5,362,400	No	4	S	Indirect	See Footnote
Common Stock, Par Value $0.001 Per Share	Disposition	2020-08-17	126,888	$50.15	5,235,512	No	4	S	Indirect	See Footnote
Common Stock, Par Value $0.001 Per Share	Disposition	2020-08-17	1,235,512	$46.75	4,000,000	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	21,028	Direct

Footnotes

These shares are held by Genextra S.p.A. Mr. Fundaro is the Chief Executive Officer of Genextra S.p.A. and, in such capacity, Mr. Fundaro exercises voting control over the shares of common stock owned by Genextra S.p.A and investment control over such shares as authorized by the board of Genextra S.p.A. Mr. Fundaro disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
Genextra S.p.A. will apply the proceeds from the sales to pay off outstanding indebtedness under its margin loan secured by its shares of Intercept's common stock, and for general corporate purposes.